KLRS
Kalaris Therapeutics, Inc. Common Stock
KLRS
KLRS
87 hedge funds and large institutions have $294M invested in Kalaris Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 35 increasing their positions, 22 reducing their positions, and 16 closing their positions.
Holders
87
Holders Change
+3
Holders Change %
+3.57%
% of All Funds
1.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
35
Reduced
22
Closed
16
Calls
$267K
Puts
$180K
Net Calls
+$87K
Net Calls Change
-$42K
Top Buyers
| 1 |
AG
1
Artal Group
Luxembourg
|
$44M |
| 2 |
2
Alkeon Capital Management
New York
|
$38.8M |
| 3 |
RG
3
Redmile Group
San Francisco,
California
|
$15.1M |
| 4 |
GC
4
GMT Capital
Atlanta,
Georgia
|
$21.8M |
| 5 |
5
Vanguard Group
Malvern,
Pennsylvania
|
$23M |
Top Sellers
| 1 |
1
JPMorgan Chase & Co
New York
|
$4.81M |
| 2 |
2
Goldman Sachs
New York
|
$1.37M |
| 3 |
3
Barclays
London,
United Kingdom
|
$167K |
| 4 |
4
State of Wisconsin Investment Board
Madison,
Wisconsin
|
$1.53M |
| 5 |
5
Two Sigma Investments
New York
|
$0 |
